A Pilot Phase 2 Study of Albumin-Bound Rapamycin Nanoparticles, ABI-009, in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors (NETs) of the Lung or Gastroenteropancreatic System

Authors
Publication date
1 March 2019
Publisher
'Ovid Technologies (Wolters Kluwer Health)'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    University of Queensland eSpace

    redirect
    oaioai:espace.library.uq.edu.au:U...
    Last time updated on 03/05/2019